GALT (Galectin Therapeutics) Institutional Ownership: 24.54% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GALT Galectin Therapeutics Inc GALT
27 GF Score
Price $4.76
! 5 Warning Signs
View Full Analysis

What is Galectin Therapeutics Institutional Ownership?

Galectin Therapeutics GALT -10.53% 27 Institutional Ownership is 24.54% as of Jul. 16, 2026. GuruFocus rates GALT with a GF Score™ of 27/100. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Galectin Therapeutics's institutional ownership is 24.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Galectin Therapeutics's Insider Ownership is 24.82%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Galectin Therapeutics's Float Percentage Of Total Shares Outstanding is 63.74%.

Galectin Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Galectin Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galectin Therapeutics Institutional Ownership Chart

Galectin Therapeutics Historical Data

The historical data trend for Galectin Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 7.33 7.33 7.47 7.08 7.07 7.40 6.50 6.28 6.26 8.98
GALT
27GF Score
Galectin Therapeutics Inc GALT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galectin Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 24.54% mean?
Galectin Therapeutics (GALT) has a Institutional Ownership of 24.54% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Galectin Therapeutics and its competitors.
Is Galectin Therapeutics' Institutional Ownership too high?
Galectin Therapeutics' current Institutional Ownership is 24.54%. Overall, Galectin Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galectin Therapeutics' Institutional Ownership compare to PALI and IRD?
Galectin Therapeutics' Institutional Ownership of 24.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Galectin Therapeutics and its competitors. Galectin Therapeutics's current Institutional Ownership is 24.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galectin Therapeutics stock overvalued right now?
Galectin Therapeutics (GALT) has a current Institutional Ownership of 24.54%. The current Institutional Ownership is 24.54%. Galectin Therapeutics' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Galectin Therapeutics (GALT), the current Institutional Ownership is 24.54% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galectin Therapeutics Business Description

Other Exchanges PHPN:Germany
Address 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
27GF Score

Get the complete analysis for GALT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price